One day radiation may become an option for breast cancer patientsJanuary 04, 2006Doctors in Canada are studying the effectiveness of permanent radiation seed implants following lumpectomy as an alternative to whole or partial breast irradiation for early-stage breast cancer patients, according to a study published in the January 1, 2006, issue of the International Journal of Radiation OncologyBiologyPhysics, the official journal of ASTRO, the American Society for Therapeutic Radiology and Oncology. This type of radiation would cut treatment time for certain patients from several weeks to one day. For early stage breast cancer, women often undergo a lumpectomy to remove the tumor followed by radiation therapy to kill any cancer cells that may remain. Most women undergo external beam radiation, which is given every day, Monday through Friday, for six to eight weeks. Doctors have been experimenting with ways to shorten this treatment. One technique used by a growing number of radiation oncologists involves the use of temporary radiation implants. These radiation sources are delivered through a catheter into the breast, usually twice a day for one week. In this study, the first of its kind in the world, doctors wanted to see if it was possible to use permanent implants, like what many men receive to treat prostate cancer, to combat the cancer with only one treatment. These implants, about the size of a grain of rice, would not be removed daily like with the temporary implants. Rather, the radioactive seeds would deliver radiation to the breast area for a number of weeks until they were no longer radioactive. The advantage over the temporary implants is that the patient only has to undergo one surgical procedure to receive the radiation, versus 10 treatments over one week for temporary implants. The current treatment standard of lumpectomy followed by external beam radiation therapy is proven to keep the cancer from returning, but 38 percent of women develop significant toxicity, which can compromise their quality of life. According to early returns from the study, which began in May 2004, 44 patients have been treated successfully with the permanent implants. So far, none have evidence of their cancer returning and acute skin irritation is six times less frequent when compared to external beam radiation. "The main motivation was to see if we could reduce the burden of treatment for women suffering from early-stage breast cancer," said Jean-Philippe Pignol, M.D., Ph.D., lead author of the study and radiation oncologist at Sunnybrook and Women's College Health Sciences Centre in Toronto, Ontario, Canada. "The seed implants reduce the treatment to a one-time event compared to the current standard of daily treatments over many weeks. The seeds also reduce the amount of radiation the normal breast tissue receives, which lessens the chance of the patient developing problems that affect their post-cancer quality of life. The great thing is that the patient can go home right after the procedure and live a normal life while receiving her radiation." American Society for Therapeutic Radiology and Oncology |
|||||||||||||||||||||
| Related Breast Cancer Current Events and Breast Cancer News Articles Menopause-cardiology consensus statement on cardiovascular disease and on HRT A menopause-cardiology consensus statement has called for direct action to prevent cardiovascular disease (CVD) in menopausal women. The statement also concludes that there is little evidence of increased CVD risk in taking HRT. Researchers Identify Role of Gene in Tumor Development, Growth and Progression Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. UCLA researchers create 'fly paper' to capture circulating cancer cells Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor. Fertility procedures need not delay breast cancer treatment for younger women A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion. Coffee break: Compound brewing new research in colon, breast cancer A compound in coffee has been found to be estrogenic in studies by Texas AgriLife Research scientists. Drugs to treat anemia in cancer patients linked to thromboembolism Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. Discovery in worms by Queen's researchers points to more targeted cancer treatment Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment. FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. Carnegie Mellon researchers link health-care debate to risk of dying in US and Europe The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated. Scientists uncover new key to the puzzle of hormone therapy and breast cancer The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer. More Breast Cancer Current Events and Breast Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||